Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape

OBJECTIVE: Tissue plasminogen activator (tPA) is considered standard of care for acute ischemic stroke treatment, but some physicians withhold or delay this highly time‐dependent therapy from stroke patients because they do not think it works well or they are worried about the adverse effects or fea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganti, Latha, Kwon, Bryan, George, Andrew, Stead, Thor, Plamoottil, Cherian, Banerjee, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783382/
https://www.ncbi.nlm.nih.gov/pubmed/35112099
http://dx.doi.org/10.1002/emp2.12646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783382/
https://www.ncbi.nlm.nih.gov/pubmed/35112099
http://dx.doi.org/10.1002/emp2.12646

Ejemplares similares